
|Videos|June 19, 2015
Combination of Panobinostat and Carfilzomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Author(s)Jesus G. Berdeja, MD
Jesus G. Berdeja, MD, director of Myeloma Research, senior investigator, Hematologic Malignancies Principal Investigator, Sarah Cannon Research Institute, discusses a phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
3
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
4
Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer
5
































